News | February 09, 2022
Glenmark launches nasal spray to treat Covid-19
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The company will donate 5000 nebulizers to primary health care centres in rural India
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Subscribe To Our Newsletter & Stay Updated
